Application of the adverse outcome pathway framework to genotoxic modes of action
Jennifer C. Sasaki(Kaiser Permanente South San Francisco Medical Center), Maik Schuler(Pfizer (United States)), Sheila M. Galloway(United States Military Academy), Azeddine Elhajouji(Novartis (Switzerland)), Laura Custer(Bristol-Myers Squibb (United States)), Ulrike Hemmann(Sanofi (Germany)), Giel Hendriks(Leiden University), Steven M. Bryce(Litron Laboratories (United States)), Heng‐Hong Li(Georgetown University), Ashley Allemang(Procter & Gamble (United States)), Daniel J. Roberts(Charles River Laboratories (Netherlands)), Jan van Benthem(National Institute for Public Health and the Environment), Kerry L. Dearfield(Food Safety and Inspection Service), Gladys Ouédraogo(L'Oréal (France)), Albert J. Fornace(Georgetown University), Carole L. Yauk(Health Canada), Yasmin Dietz(Sanofi (France)), Mirjam Luijten(National Institute for Public Health and the Environment), Patricia A. Escobar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Véronique Thybaud(Sanofi (France)), Lauren Peel(Health and Environmental Sciences Institute), Roland Froetschl(Federal Institute for Drugs and Medical Devices), Stefan Pfuhler(Procter & Gamble (Switzerland))
Cited by 56
Related Papers
Chromosome aberrations and sister chromatid exchanges in chinese hamster ovary cells: Evaluations of 108 chemicals
|Environmental and Molecular Mutagenesis|1987|661
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
|Regulatory Toxicology and Pharmacology|2006|461
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2007|437
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
|Scientific Reports|2016|425